OS Therapies OSTX Chief Operating Decision Maker — Research And Development Expense

Similar metrics at other companies

RNTXClinical Operation Activities — Research And Development Expense

$1.96M+191%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

MPLTAll Other Segments — Research And Development Expense

$933K+22.6%

GERNResearch and clinical expenses — R&D

$13M-5.1%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

Questions, answered.

What is OS Therapies's chief operating decision maker — research and development expense?

OS Therapies (OSTX) reported chief operating decision maker — research and development expense of $7.35M in Q1 2026.

How has OS Therapies's chief operating decision maker — research and development expense changed year-over-year?

OS Therapies's chief operating decision maker — research and development expense increased by 461.6% year-over-year, from $1.31M to $7.35M.

What does chief operating decision maker — research and development expense mean?

Represents the costs incurred by the primary operating segment for research and development activities, including clinical trials and drug discovery efforts. This metric reflects the company's investment in its pipeline of therapeutic candidates for oncology treatments. Monitoring this expense provides insight into the company's commitment to innovation and clinical advancement.